FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

J&J sales up; profits down on charges

Tools

Johnson & Johnson reported a 19 percent decline in fourth-quarter earnings largely because of restructuring charges, but posted a 9 percent sales gain that reversed a slump in previous quarters. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about pharmaceutical sales and marketing   Johnson & Johnson